```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:sssptau153cxa

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  May 12   EXTEND option available in structure searching
 NEWS  4  May 12   Polymer links for the POLYLINK command completed in REGISTRY
 NEWS  5  May 27   New UPM (Update Code Maximum) field for more efficient patent
                   SDIs in CAplus
 NEWS  6  May 27   CAplus super roles and document types searchable in REGISTRY
 NEWS  7  Jun 28   Additional enzyme-catalyzed reactions added to CASREACT
 NEWS  8  Jun 28   ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG,
                   and WATER from CSA now available on STN(R)
 NEWS  9  Jul 12   BEILSTEIN enhanced with new display and select options,
                   resulting in a closer connection to BABS
 NEWS 10  Jul 30   BEILSTEIN on STN workshop to be held August 24 in conjunction
                   with the 228th ACS National Meeting
 NEWS 11  AUG 02   IFIPAT/IFIUDB/IFICDB reloaded with new search and display
                   fields
 NEWS 12  AUG 02   CAplus and CA patent records enhanced with European and Japan
                   Patent Office Classifications
 NEWS 13  AUG 02   STN User Update to be held August 22 in conjunction with the
                   228th ACS National Meeting
 NEWS 14  AUG 02   The Analysis Edition of STN Express with Discover!
                   (Version 7.01 for Windows) now available
 NEWS 15  AUG 04   Pricing for the Save Answers for SciFinder Wizard within
                   STN Express with Discover! will change September 1, 2004

 NEWS EXPRESS  JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:22:43 ON 06 AUG 2004

=> file caplus uspatful japio europatful medline biosis embase scisearch
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
```

```
                                                        ENTRY     SESSION
FULL ESTIMATED COST                                      0.21        0.21

FILE 'CAPLUS' ENTERED AT 17:23:12 ON 06 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 17:23:12 ON 06 AUG 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 17:23:12 ON 06 AUG 2004
COPYRIGHT (C) 2004 Japanese Patent Office (JPO)- JAPIO

FILE 'EUROPATFULL' ENTERED AT 17:23:12 ON 06 AUG 2004
COPYRIGHT (c) 2004 WILA Verlag Muenchen (WILA)

FILE 'MEDLINE' ENTERED AT 17:23:12 ON 06 AUG 2004

FILE 'BIOSIS' ENTERED AT 17:23:12 ON 06 AUG 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 17:23:12 ON 06 AUG 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 17:23:12 ON 06 AUG 2004
COPYRIGHT 2004 THOMSON ISI

=> s (mucosal? or transmucosal?) and aqueous?
L1       17170 (MUCOSAL? OR TRANSMUCOSAL?) AND AQUEOUS?

=> s ((osmotic pressure) or osmolarity)
L2       79047 ((OSMOTIC PRESSURE) OR OSMOLARITY)

=> s l1 and l2
L3        1205 L1 AND L2

=> s l3 and mOsm
L4         204 L3 AND MOSM

=> s l4 and (290 mOsm)
L5           6 L4 AND (290 MOSM)

=> d l5 1-6 ibib abs

L5   ANSWER 1 OF 6  USPATFULL on STN
ACCESSION NUMBER:       2003:89399  USPATFULL
TITLE:                  Non-peptide inhibition of T-lymphocyte activation and
                        therapies related thereto
INVENTOR(S):            Chandy, K. George, Laguna Beach, CA, United States
                        Wulff, Heike, Irvine, CA, United States
                        Cahalan, Michael D., Laguna Beach, CA, United States
                        Grismer, Stephan, Blaustein, GERMANY, FEDERAL REPUBLIC
                        OF
                        Rauer, Heiko J., Irvine, CA, United States
                        Miller, Mark J., Brea, CA, United States
PATENT ASSIGNEE(S):     The Regents of the University of California, Oakland,
                        CA, United States (U.S. corporation)

                             NUMBER        KIND    DATE
                        ---------------- ------ --------
PATENT INFORMATION:     US 6541494          B1   20030401
APPLICATION INFO.:      US 2000-479391           20000106  (9)
DOCUMENT TYPE:          Utility
FILE SEGMENT:           GRANTED
```

PRIMARY EXAMINER: Travers, Russell
LEGAL REPRESENTATIVE: Buyan, Robert D., Stout, Uxa, Buyan & Mullins, LLP
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 1387
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds, preparations and methods for immunosuppressive treatment of autoimmune disorders, graft rejection and/or graft/host disease. Therapeutically effective amounts of certain substituted triarylmethane compounds, such as 1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole, are administered to mammalian patients to selectively inhibit the calcium-activated K.sup.+ channel (IKCa1) in lymphocytes, monocytes, macrophages, platelets or endothelial cells without concomitant inhibition of P450-dependent enzyme systems, resulting in reduction of antigen-, cytokine-, or mitogen-induced calcium entry through store operated calcium channels in these cells, suppression of cytokine production by these cells, and inhibition of activation of these cells. Such inhibition of the Ca.sup.++ activated K.sup.+ channel (IKCa1) prevents the pre-Ca.sup.++ stage of cell activation and thus causes immunosuppression and an anti-inflammatory response.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 6 USPATFULL on STN
ACCESSION NUMBER: 2002:295175 USPATFULL
TITLE: Mediators of hedgehog signaling pathways, compositions and uses related thereto
INVENTOR(S): Baxter, Anthony David, Hertfordshire, UNITED KINGDOM
Boyd, Edward Andrew, Oxfordshire, UNITED KINGDOM
Guicherit, Oivin M., Belmont, MA, UNITED STATES
Price, Stephen, Buckinghamshire, UNITED KINGDOM
Rubin, Lee L., Wellesley, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002165221	A1	20021107
APPLICATION INFO.:	US 2001-977096	A1	20011012 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-240536P	20001013 (60)
	US 2000-240564P	20001013 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ROPES & GRAY, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624
NUMBER OF CLAIMS: 92
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 58 Drawing Page(s)
LINE COUNT: 5140
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist, such as a small molecule, in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 6 USPATFULL on STN
ACCESSION NUMBER: 2002:105654 USPATFULL
TITLE: Nicotine **mucosal** spray

INVENTOR(S): Jones, Richard L., Edmonton, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002054856	A1	20020509
	US 6596740	B2	20030722
APPLICATION INFO.:	US 2001-983554	A1	20011024 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-243205P	20001024 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Anita Nador, Bereskin & Parr, 40 King Street West, Box 401, Toronto, ON, M5H 3Y2
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 737
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A composition for administration to the nasal mucosa of a subject comprises a solution of nicotine or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable solvent. The composition has a nicotine concentration less than 10 mg/ml. The composition used alone assists in reduction of the desire of a subject to smoke tobacco. It also reduces the nasal symptoms associated with administration of higher concentrations of nicotine to the nasal mucosa.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 6 USPATFULL on STN
ACCESSION NUMBER: 93:7131 USPATFULL
TITLE: Treatment of osmotic disturbance with organic osmolytes
INVENTOR(S): Gullans, Steven R., Natick, MA, United States
Heilig, Charles W., Needham, MA, United States
PATENT ASSIGNEE(S): Brigham and Women's Hospital, Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5182299		19930126
APPLICATION INFO.:	US 1991-670779		19910319 (7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1990-495575, filed on 19 Mar 1990, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Raymond, Richard L.
ASSISTANT EXAMINER: Hollinden, Gary E.
LEGAL REPRESENTATIVE: Sterne, Kessler, Goldstein & Fox
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 26 Drawing Figure(s); 23 Drawing Page(s)
LINE COUNT: 2185
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of treating an osmotic disturbance in an animal which comprises administering to an animal an effective amount of an organic osmolyte, wherein the organic osmolyte is a polyol. Specific polyols include myo-inositol and sorbitol. Also included are precursors of organic osmolytes including precursors of polyols. Other polyol precursors are selected from the group consisting of glucose, glucose polymers, and glycerol. Also inclu

This invention was funded by a research grant from the National Institutes of Health, 1RO1 DK36031, which provides to the United States Government certain rights in the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 6 JAPIO (C) 2004 JPO on STN
ACCESSION NUMBER: 2004-099624 JAPIO
TITLE: MEDICINAL COMPOSITION FOR ADMINISTRATION TO MUCOSA
INVENTOR: NISHIBE YOSHIHISA; KINOSHITA WATARU; KAWABE HIROYUKI
PATENT ASSIGNEE(S): TEIJIN LTD
PATENT INFORMATION:

PATENT NO	KIND	DATE	ERA	MAIN IPC
JP 2004099624	A	20040402	Heisei	A61K009-10

APPLICATION INFORMATION
STN FORMAT: JP 2003-430651 20031225
ORIGINAL: JP2003430651 Heisei
PRIORITY APPLN. INFO.: JP 1998-110887 19980421
PRIORITY APPLN. INFO.: JP 1998-110888 19980421
SOURCE: PATENT ABSTRACTS OF JAPAN (CD-ROM), Unexamined Applications, Vol. 2004
AN 2004-099624 JAPIO
AB PROBLEM TO BE SOLVED: To provide a new medicinal composition for administration to mucosa and having low **osmotic pressure**
.
SOLUTION: The medicinal composition for administration to mucosa and for application to pharmacotherapy comprises a water-insoluble and/or slightly water-soluble material and an **aqueous** medium and has less than **290 mOsm osmotic pressure.** The composition has superior transitivity in blood to conventional medicinal compositions for administration to musca. And a composition for administration to mucosa, comprising a hemostatic agent and a medicament, is provided. The composition has superior osmosis and retention in the **mucosal** tissue to the conventional medicinal compositions.

L5 ANSWER 6 OF 6 EUROPATFULL on STN

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 619729 EUROPATFULL EW 199928 FS PS
TITLE: COMPOSITION TO HELP STOP SMOKING.
ZUSAMMENSETZUNG ZUR RAUCHERENTWOeHNUNG.
COMPOSITION ET PROCEDE DE SUPPLEANCE AU TABAGISME.
INVENTOR(S): JONES, Richard, L., 10928 - 81 Street, Edmonton, Alberta T5H 1L5, CA
PATENT ASSIGNEE(S): Pharmacia & Upjohn Aktiebolag, 112 87 Stockholm, SE
PATENT ASSIGNEE NO: 1720686
AGENT: Bannerman, David Gardner et al, Withers & Rogers, Goldings House, 2 Hays Lane, London SE1 2HW, GB
AGENT NUMBER: 28001
OTHER SOURCE: EPB1999039 EP 0619729 B1 990714
SOURCE: Wila-EPS-1999-H28-T1
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE
PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung)
PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 619729	B1	19990714
'OFFENLEGUNGS' DATE:		19941019
APPLICATION INFO.:	EP 1993-901989	19930104

PRIORITY APPLN. INFO.: GB 1992-47 19920103
RELATED DOC. INFO.: WO 93-CA3 930104 INTAKZ
WO 9312764 930708 INTPNR
REFERENCE PAT. INFO.: DE 3241437 A GB 2030862 A
GB 2133691 A US 4920989 A
US 4953572 A
REF. NON-PATENT-LIT.: DATABASE WPIL Week 8414, Derwent Publications Ltd., London, GB; AN 84-086173 (14)

=> d l5 3 HIT

L5 ANSWER 3 OF 6 USPATFULL on STN
TI Nicotine **mucosal** spray
SUMM [0002] The invention relates to the field of nicotine **mucosal** sprays, to compositions comprising nicotine that can be administered in a **mucosal** spray form and to methods and uses therefore. In one embodiment, the invention relates to compositions and methods useful for subjects who wish to reduce tobacco smoking.

DETD [0030] The term "pharmaceutically acceptable solven." means a solvent that is physiologically tolerable at the dosage administered. Nicotine is soluble in water but an **aqueous** solvent should have it's pH adjusted with buffers and it's **osmolarity** adjusted into the physiological range. Those skilled ii the art will know how to accomplish these adjustments.
DETD [0035] It is desirable that nasal administration of nicotine provides a sufficient dose of nicotine to a sufficiently large area of the nasal mucosa to give the desired rapid increase in blood nicotine level without providing a local nicotine concentration so high that it causes **mucosal** irritation and without requiring the delivery of such a large volume of nicotine-containing composition that a portion of the administered dose runs from the nose, causing annoyance and inconvenience to the user.
DETD [0052] Five concentrations of NNS where prepared from base solution containing 10 mg/ml nicotine. The (-) isomer of nicotine (the naturally occurring form) was obtained from Sigma-Aldrich Canada Ltd (Oakville, ON, Cat# N3876). To make the 10 mg/ml nicotine solution, 1 gm of nicotine was dissolved in 100 ml phosphate-buffered saline. Phosphate-buffed saline (PBS) was prepared bi, adding 0.71 gm Na.sub.2HPO.sub.4 and 0.69 gm Na.sub.2HPO.sub.4 to sterile distilled H.sub.2O to make 10 ml. Then 0.92 gm NaCl was added. The resulting solution had a pH of 6.8 and a 1 **osmolarity** of **290 mOsm.** The five lower nicotine concentrations contained 9, 7, 5, 3 and 1 mg/ml of nicotine. The 9 mg/ml solution was prepared by diluting 18 ml of the base solution (10 mg/ml) with 2 ml PBS. The 7 mg/ml solution contained 14 ml of the base solution and 6 ml of PBS, the 5 mg/ml solution contained 14 ml of the base solution and 14 ml PBS, the 3 mg/ml solution contained 6 ml of the base solution and 14 ml PBS and the 1 mg/ml solution contained 2 ml of the base and 18 ml PBS. The viscosity of the solutions was near 1.0 cps (similar to water).

=> d his

(FILE 'HOME' ENTERED AT 17:22:43 ON 06 AUG 2004)

FILE 'CAPLUS, USPATFULL, JAPIO, EUROPATFULL, MEDLINE, BIOSIS, EMBASE, SCISEARCH' ENTERED AT 17:23:12 ON 06 AUG 2004
L1 17170 S (MUCOSAL? OR TRANSMUCOSAL?) AND AQUEOUS?
L2 79047 S ((OSMOTIC PRESSURE) OR OSMOLARITY)
L3 1205 S L1 AND L2
L4 204 S L3 AND MOSM
L5 6 S L4 AND (290 MOSM)

```
=> s l4 and bioavailability
L6          135 L4 AND BIOAVAILABILITY

=> s l6 and hypotonic?
L7            4 L6 AND HYPOTONIC?

=> d l7 1-4 ibib abs

L7   ANSWER 1 OF 4  USPATFULL on STN
ACCESSION NUMBER:        2003:194115  USPATFULL
TITLE:                   Monobactam compositions and methods of use thereof
INVENTOR(S):             Shawar, Ribhi M., Bellevue, WA, UNITED STATES

                              NUMBER        KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2003133925      A1   20030717
APPLICATION INFO.:       US 2002-256341     A1   20020926  (10)

                              NUMBER         DATE
                         ------------------ --------
PRIORITY INFORMATION:    US 2001-325933P    20010928 (60)
DOCUMENT TYPE:           Utility
FILE SEGMENT:            APPLICATION
LEGAL REPRESENTATIVE:    Chiron Corporation, Intellectual Property, P.O. Box
                         8097, Emeryville, CA, 94662-8097
NUMBER OF CLAIMS:        15
EXEMPLARY CLAIM:         1
NUMBER OF DRAWINGS:      4 Drawing Page(s)
LINE COUNT:              849
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB       Methods, compounds and compositions are provided for inhibiting the
         growth of pathogenic microbes in vitro and of treatment of pathogenic
         bacterial infections in vivo using an antibacterial monobactam compound
         and a mucolytic agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7   ANSWER 2 OF 4  USPATFULL on STN
ACCESSION NUMBER:        2003:187438  USPATFULL
TITLE:                   Topical formulations of natamycin/pimaricin
INVENTOR(S):             Andersson, Borje S., Houston, TX, UNITED STATES
PATENT ASSIGNEE(S):      Board of Regents, The University of Texas System (U.S.
                         corporation)

                              NUMBER        KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2003129225      A1   20030710
APPLICATION INFO.:       US 2002-294491     A1   20021114  (10)

                              NUMBER         DATE
                         ------------------ --------
PRIORITY INFORMATION:    US 2001-332806P    20011114 (60)
DOCUMENT TYPE:           Utility
FILE SEGMENT:            APPLICATION
LEGAL REPRESENTATIVE:    FULBRIGHT & JAWORSKI L.L.P., A REGISTERED LIMITED
                         LIABILITY PARTNERSHIP, 600 CONGRESS AVENUE, SUITE 2400,
                         AUSTIN, TX, 78701-3271
NUMBER OF CLAIMS:        36
EXEMPLARY CLAIM:         1
NUMBER OF DRAWINGS:      1 Drawing Page(s)
LINE COUNT:              1498
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB       The present invention relates to formulations of Pimaricin (also called
         Natamycin), that are useful for the treatment and suppression of topical
         infections such as those caused by various pathogens including molds and
```

yeast, that are resistant to azole compounds and to Amphotericin B. Methods for treatment of infections are also set forth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 4 USPATFULL on STN

ACCESSION NUMBER:	2002:192071 USPATFULL			
TITLE:	FORMULATED NUCLEIC ACID COMPOSITIONS AND METHODS OF ADMINISTERING THE SAME FOR GENE THERAPY			
INVENTOR(S):	ROLLAND, ALAIN, THE WOODLAND, TX, UNITED STATES MUMPER, RUSSELL J., THE WOODLAND, TX, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002103142	A1	20020801	
	US 6514947	B2	20030204	
APPLICATION INFO.:	US 1997-798974	A1	19970211	(8)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	LYON & LYON LLP/ VALENTIS INC., 633 WEST FIFTH STREET, SUITE 4700, LOS ANGELES, CA, 90071-2066			
NUMBER OF CLAIMS:	55			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	11 Drawing Page(s)			
LINE COUNT:	2413			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for administering nucleic acid compositions in vitro to cells in culture or in vivo to an organism whereby the uptake of nucleic acids is enhanced are provided. Various compositions, including those incorporating protective, interactive, non-condensing compounds, are utilized to protect and administered nucleic acid formulation, thereby prolonging the localized **bioavailability** of the administered nucleic acid and enhancing expression from the nucleic acid.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 4 USPATFULL on STN

ACCESSION NUMBER:	2002:119301 USPATFULL			
TITLE:	Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis			
INVENTOR(S):	Osbakken, Robert S., Camarillo, CA, UNITED STATES Hale, Mary Anne, Woodland Hills, CA, UNITED STATES Leivo, Frederick T., Carpinteria, CA, UNITED STATES Munk, James D., Camarillo, CA, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002061281	A1	20020523	
APPLICATION INFO.:	US 2001-942959	A1	20010831	(9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2000-US18410, filed on 5 Jul 2000, UNKNOWN Continuation-in-part of Ser. No. US 2000-577623, filed on 25 May 2000, PENDING			
	NUMBER	DATE		
PRIORITY INFORMATION:	US 1999-142618P	19990706	(60)	
	US 1999-142620P	19990706	(60)	
	US 1999-142621P	19990706	(60)	
	US 1999-142622P	19990706	(60)	
	US 1999-142624P	19990706	(60)	
	US 1999-142741P	19990706	(60)	
	US 1999-142881P	19990706	(60)	
	US 2000-193507P	20000403	(60)	
	US 2000-193508P	20000403	(60)	

	US 2000-193509P	20000403 (60)
	US 2000-193510P	20000403 (60)
	US 2000-194078P	20000403 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MORGAN, LEWIS & BOCKIUS, 1800 M STREET NW, WASHINGTON, DC, 20036-5869	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	1893	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutical compositions are described that comprise one or more active ingredients selected from the group consisting of an anti-infective agent, anti-inflammatory agent, anti-mucolytic agent, antihistamine, an antiseptic, and antibiotic combinations or combinations of others of these classes of ingredients, and particularly to compositions formulated as a solution or suspension in a unit dose for aerosol administration to treat chronic sinusitis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>